Navigation Links
Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Date:12/10/2008

SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commencement of patient dosing for a Phase 1 clinical trial for a bisphosphonate administered with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) injection. This study will explore the safety, tolerability and pharmacokinetics of SC administration of a bisphosphonate plus rHuPH20. Currently, injectable bisphosphonates must be administered intravenously (IV).

"We are pleased that the first clinical trial is underway for our bisphosphonate program, our third proprietary product development initiative to enter clinical studies," stated Jonathan Lim, M.D., President and CEO of Halozyme Therapeutics. "The bisphosphonate program joins insulin, for diabetes, and Chemophase, for superficial bladder cancer, our other two proprietary programs in clinical development. The goal of Halozyme's bisphosphonate program is to provide an alternative dosage formulation that may offer greater convenience, compliance and tolerability to patients for the treatment of osteoporosis."

This Phase 1 dose ranging clinical trial will assess the safety, tolerability and pharmacokinetics of a bisphosphonate with and without co-administration of rHuPH20 across a range of bisphosphonate concentrations and volumes and various rHuPH20 doses. The study will also compare SC administration of a bisphosphonate plus rHuPH20 to IV bisphosphonate alone.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for t
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
2. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
5. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
8. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
9. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Calif., Feb. 27, 2015 Isis Pharmaceuticals, Inc. ... outperformed both its pro forma net operating loss (NOL) ... a strong financial position.  Isis, significantly improved financial results ... $230 million in payments the Company received from its ... 2014 was a nearly 60% improvement over its 2013 ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: ... announced today the appointment of Mr. Kenneth Lee as a ... 31, 2011 to replace Mr. Xianping Wang who resigned from ... Lee is a Principal at SAIF Partners, a leading growth ...
... May 31, 2011 Volcano Corporation (NASDAQ: VOLC ... and therapy guidance tools designed to enhance the treatment of ... be participating in the Goldman Sachs 32nd Annual Global Healthcare ... begin at 2:40 p.m., Pacific Daylight Time (5:40 p.m., Eastern ...
Cached Medicine Technology:Sinovac Appoints Kenneth Lee to Board of Directors 2
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... 28, 2015 The Mesothelioma Applied ... awards at the International Symposium on Malignant Mesothelioma on ... at the Hyatt Regency Bethesda in Bethesda, Maryland. The ... work and commitment to the mission to cure mesothelioma. ... will be presented to Miriam Ratner. Miriam runs the ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 ... organization has sponsored visitor health insurance programs for visitors ... years. Most Indian elderly parents traveling to the United ... such as diabetes and blood pressure. These diseases are ... not even list them as medical conditions. There were ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... West Bengal was first refused treatment by government hospitals ... human rights group intervened to unshackle him, reports said ... by the Association for the Protection of Democratic Rights ... North 24 Parganas district freed., ,Debnath had developed ...
... Watch had explored the physiology// of hot flashes experienced by ... flashes are well known to most menopausal women—and to many ... tend to come on suddenly and last from one to ... to a feeling of being on fire. , ,Although ...
... authorities are pouring cold water on hopes for a new drug ... and Drug Administration (FDA) wants more studies to be done on ... find out what long-term side effects the drug may induce, the ... "female Viagra" as it promises to restore healthy sexual appetites to ...
... pollution levels may have an increased chance of a heart ... ,The research done by scientists from Loma Linda University had ... Environmental Health Perspectives. Their research findings suggest that the rate ... more if they happen to live in areas that have ...
... ,Chennai's Adyar Cancer Institute director Dr.V. Shanta is among ... was awarded the prize for public service and her "untiring ... and compassion for the study and treatment of cancer// in ... She has also won a number of national and international ...
... from kidney diseases may have increased risk of death ... from Johns Hopkins University School of Medicine have found ... peritoneal dialysis over hemodialysis increases their risk of dying ... published in the journal Annals of Internal Medicine online ...
Cached Medicine News:Health News:Insight for Hot Flashes In Postmenopausal Women 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Air Pollution Increases Risk For Heart Disease In Women 2Health News:Magsaysay Award for Dr.Shanta from Chennai Cancer Institute 2Health News:Choice Of Treatment Increases Risk Of Death In Kidney Disease 2